The Neuromuscular Disease Network for Canada

funder-logos_nmd4c

Maryam Oskoui

maryam-oskoui

Director, Division of Pediatric Neurology, Department of Pediatric, Montreal Children’s Hospital

Associate Professor, Departments of Pediatrics and Neurology and Neurosurgery, McGill University | Scientist, Research Institute of the McGill University Health Centre

Email Maryam

Read more about Maryam

Biography

Dr. Maryam Oskoui is a pediatric neurologist, neurophysiologist and epidemiologist. She is a Clinician Scientist and Director of Pediatric Neurology at the Montreal Children’s Hospital. She is a Senior Clinical Research Scholar of the FRQ-S with a focus in clinical research and clinical trials in pediatric neuromuscular disorders and has contributed to over 100 peer reviewed publications. She is a Principal investigator and SMA lead for INFORM RARE, a Strategy for Patient Oriented Research innovative clinical trial initiative supported by CIHR.

 

Dr. Oskoui serves as an evidence-based methodologist for the American Academy of Neurology and has contributed to numerous clinical care guidelines. As part of NMD4C, she is developing clinical guidelines through the Knowledge Translation Team. She contributes to the Canadian Neuromuscular community by serving as a member of the Scientific Advisory Committee for Muscular Dystrophy Canada and chairing the Canadian Pediatric Neuromuscular Group and the Canadian Neuromuscular Disease Registry’s Spinal Muscular Atrophy Working Group. She is a Board member for the Association des Neurologues du Quebec.

 

Dr. Oskoui completed her medical school and pediatric neurology residency at McGill University (Montreal, Canada), neuromuscular clinical and research fellowship at Columbia University (New York, USA) and Master’s of Science in Clinical Epidemiology at McGill University.

Recent publications

Redline, RW, Vik, T, Heerema-McKenney, A, Jamtoy, AH, Ravishankar, S, Ton Nu, TN et al.. Interobserver Reliability for Identifying Specific Patterns of Placental Injury as Defined by the Amsterdam Classification. Arch Pathol Lab Med. 2021. PMID:34252177

Oskoui, M, Gonorazky, H, McMillan, HJ, Dowling, JJ, Amin, R, Gagnon, C et al.. Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective. Can J Neurol Sci. 2021. 1-11 PMID:34082851

Dangouloff, T, Vrščaj, E, Servais, L, Osredkar, D, SMA NBS World Study Group. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscul Disord. 2021.31 (6)574-582 PMID:33985857

Gorter, JW, Amaria, K, Kovacs, A, Rozenblum, R, Thabane, L, Galuppi, B et al.. CHILD-BRIGHT READYorNot Brain-Based Disabilities Trial: protocol of a randomised controlled trial (RCT) investigating the effectiveness of a patient-facing e-health intervention designed to enhance healthcare transition readiness in youth. BMJ Open. 2021.11 (3)e048756 PMID:33771833

Servais, L, Baranello, G, Scoto, M, Daron, A, Oskoui, M. Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opin Investig Drugs. 2021.30 (5)519-527 PMID:33749510

See more on PubMed